Which has faster onset, BLT or EMLA?

BLT cream has substantially faster onset than EMLA. Compound BLT (Benzocaine 20% + Lidocaine 10% + Tetracaine 10%) achieves clinical onset in approximately 15 minutes — the Benzocaine component penetrates the outer epidermis fast and produces the early numbing sensation, while Lidocaine and Tetracaine follow into the deeper layers. EMLA (Lidocaine 2.5% + Prilocaine 2.5%) typically requires 30-60 minutes under occlusion to reach clinical onset because it lacks a fast-onset surface agent. For workflow efficiency in busy practices, the onset difference is significant: 15 minutes vs 45-60 minutes means measurably more procedures per chair per day.

Which lasts longer, BLT or EMLA?

BLT cream lasts significantly longer than EMLA. Standard compound BLT provides 2-4 hours of clinical anesthesia after onset, with the Phenylephrine vasoconstrictor extending duration toward the upper end of the range by slowing systemic absorption. Quad-agent BLT+ (MediCaine Ultra) extends duration to 3-5 hours. EMLA typically provides 1-2 hours of clinical anesthesia after onset. The duration difference matters for procedures longer than 90 minutes, multi-area treatments (face plus neck plus decolletage), and large body-surface laser sessions.

When should I use EMLA instead of BLT?

EMLA is appropriate when (a) the patient or setting cannot access a licensed provider for compound BLT, (b) the procedure is superficial and brief (IV access, simple venipuncture, minor skin biopsy on a small area), (c) the patient has documented sensitivity to Benzocaine or Tetracaine that BLT contains but EMLA does not, (d) the patient population includes infants or very young children (EMLA has more established pediatric data), or (e) the practitioner does not have the workflow control needed for the more rigorous BLT removal protocol. For everything else — aesthetic procedures, deeper dermatologic work, microneedling, laser, tattoo — BLT is the clinical preference.

CLINICAL COMPARISON

BLT VS EMLA

Q: What is the difference between BLT and EMLA?

EMLA is a commercially manufactured 1:1 eutectic mixture of Lidocaine 2.5% and Prilocaine 2.5% — total anesthetic concentration approximately 5%. Compound BLT cream contains Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% — total anesthetic concentration approximately 40%, eight times the active load of EMLA. BLT has a faster onset (~15 minutes vs 30-60 minutes for EMLA), greater depth of penetration, and longer duration (2-4 hours vs 1-2 hours). EMLA is approved for over-the-counter and prescription use in many jurisdictions; compound BLT is restricted to licensed providers.

Q: Is BLT stronger than EMLA?

Yes, by a significant margin. BLT contains approximately 40% total active anesthetic across three agents (Benzocaine 20%, Lidocaine 10%, Tetracaine 10%), often with Phenylephrine 0.5% as a vasoconstrictor. EMLA contains 5% total active anesthetic across two agents (Lidocaine 2.5%, Prilocaine 2.5%) with no vasoconstrictor. The clinical implications include faster onset, deeper tissue penetration, longer duration, and reduced bleeding at the application site for BLT. The tradeoff is that BLT requires licensed-provider access and carries higher absorption risk if applied incorrectly or over excessive surface area.

Q: Is EMLA over the counter?

EMLA is available over the counter in some jurisdictions as a low-concentration topical for minor surface anesthesia. Higher-strength formulations and bulk packaging are typically prescription. In the United States, EMLA cream is FDA-approved as a prescription product, but several lower-concentration generic Lidocaine-Prilocaine formulations are available OTC. Compound BLT is never over the counter — it is restricted to licensed providers and dispensed only after NPI verification because of its concentration.

Q: Can I use BLT and EMLA together?

Layering or combining topical anesthetics is not standard practice and is generally avoided. Mixing different formulations changes the pharmacokinetics unpredictably, increases the risk of exceeding maximum safe doses, and creates ambiguity about removal protocols. If BLT does not provide adequate anesthesia for a given procedure, the appropriate next step is regional or local injectable anesthesia, not topical layering. Step up tiers within the MediCaine line (Pro to Ultra) if more depth or duration is needed.

Q: What about BLT vs LMX 4 or LMX 5?

LMX 4 and LMX 5 are OTC single-agent Lidocaine creams at 4% and 5% concentrations, available without a prescription. They are simpler products than EMLA but share EMLA's limitations: surface-level numbing, 30-45 minute onset, 1-2 hour duration. Compound BLT outperforms LMX on all clinical metrics — onset, depth, duration, and bleeding control via Phenylephrine — but LMX is appropriate for OTC settings where compound BLT is not accessible. For licensed providers, compound BLT is the clinical standard.

Head-to-head comparison of compound BLT cream and EMLA — concentration, onset, depth, duration, regulatory access, and procedure-by-procedure recommendations for licensed providers.

SIDE BY SIDE

THE NUMBERS DON'T LIE

METRIC	COMPOUND BLT	EMLA
Active agents	3 — Benzocaine, Lidocaine, Tetracaine (+ optional Phenylephrine vasoconstrictor)	2 — Lidocaine, Prilocaine
Total active concentration	~ 40%	~ 5%
Onset	~ 15 min	30 – 60 min
Peak anesthesia	30 – 45 min	60 – 120 min
Duration	2 – 4 hr (Ultra: 3 – 5 hr)	1 – 2 hr
Depth of anesthesia	Surface + papillary + reticular dermis	Surface + papillary dermis
Vasoconstrictor	Yes (Phenylephrine 0.5%)	No
Bleeding reduction at injection	Yes	No
Occlusion required	Optional (deeper procedures)	Usually required
FDA regulatory status	503A compounded — restricted to NPI-verified providers	Rx and OTC formulations available
Pediatric data	Limited — provider judgment	Established — Rx label includes pediatric
Methemoglobinemia risk	Benzocaine (low at therapeutic dose)	Prilocaine (low at therapeutic dose)
Best for	Aesthetic injections, microneedling, laser, tattoo, dermatologic procedures	IV access, venipuncture, minor surface biopsy, pediatric

DECISION FRAMEWORK

WHICH ONE FOR WHICH PROCEDURE

CHOOSE COMPOUND BLT

✓Aesthetic procedures — fillers, Botox, lip augmentation
✓Microneedling and RF microneedling (Morpheus8, Vivace)
✓Laser hair removal, tattoo removal, fractional resurfacing
✓Professional tattoo and paramedical tattooing (licensed settings)
✓Dermatologic biopsies, Mohs surgery, cryotherapy
✓Dental injections, scaling and root planing
✓Procedures longer than 90 minutes
✓Workflows where bleeding reduction matters
✓Practices able to enforce rigorous removal protocol

Read the BLT Guide

CHOOSE EMLA

•IV access and venipuncture
•Pediatric procedures (more established pediatric data)
•Patients with documented Benzocaine or Tetracaine allergy
•Settings without NPI-verified prescribing access
•Brief, superficial procedures on small body surface areas
•OTC retail use under labeled indications

If you have NPI-verified provider access and the procedure is anything other than the above, compound BLT will outperform EMLA on every clinical metric that matters.

PHARMACOLOGY

WHY THE GAP IS SO LARGE

Concentration is not linear with effect

BLT's eight-fold higher total active concentration does not produce eight-fold more anesthesia — diminishing returns set in above ~25% total. But the gap from 5% to 40% covers the critical zone where surface-only numbing becomes dermal anesthesia. EMLA's 5% is calibrated for the epidermis. BLT's 40% reaches the reticular dermis where filler needles, biopsy punches, and laser energy do their work.

Three agents are not the same as one stronger agent

BLT's Benzocaine + Lidocaine + Tetracaine combination layers three different pharmacokinetic profiles — fast/superficial, balanced/dermal, slow/deep — producing onset, peak, and duration windows that no single agent at any concentration matches. EMLA's two agents (Lidocaine + Prilocaine) overlap heavily and produce a single broad effect window that peaks slowly.

Phenylephrine changes the math

The vasoconstrictor in MediCaine Pro and Ultra narrows cutaneous blood vessels at the application site. This (a) slows systemic absorption of the anesthetic, extending duration, (b) keeps the drug concentrated at the treatment area, deepening effect, and (c) reduces bleeding during injection-based procedures, improving the cosmetic outcome. EMLA contains no vasoconstrictor.

The base matters

MediCaine Ultra is formulated in an ointment base (mineral oil + polyethylene) that holds the high-concentration anesthetic load in prolonged skin contact. Cream and ointment bases produce different release kinetics. EMLA is cream-only, which spreads easily but evaporates and clears faster.

→ Full pharmacology on the Science page

FAQ

BLT VS EMLA QUESTIONS

What is the difference between BLT and EMLA?+

EMLA is Lidocaine 2.5% + Prilocaine 2.5% — total concentration approximately 5%. Compound BLT is Benzocaine 20% + Lidocaine 10% + Tetracaine 10% — total approximately 40%, eight times the active load. BLT has faster onset (~15 min vs 30-60 min), greater depth, and longer duration (2-4 hr vs 1-2 hr). EMLA is available OTC in some jurisdictions; compound BLT is restricted to licensed providers.

Is BLT stronger than EMLA?+

Yes, by a significant margin. BLT is ~40% total active across three agents plus a vasoconstrictor. EMLA is ~5% total across two agents with no vasoconstrictor. The clinical implications: faster onset, deeper penetration, longer duration, and reduced bleeding for BLT. The tradeoff is that BLT requires licensed-provider access and carries higher absorption risk if misapplied.

Which has faster onset?+

BLT — substantially faster. Clinical onset ~15 minutes because Benzocaine penetrates the outer epidermis fast, producing the early numbing sensation while Lidocaine and Tetracaine follow into deeper layers. EMLA typically needs 30-60 minutes under occlusion. The 30-minute workflow advantage compounds across a busy day.

Which lasts longer?+

BLT lasts longer. Standard BLT provides 2-4 hr of clinical anesthesia; quad-agent BLT+ extends to 3-5 hr. EMLA provides 1-2 hr. The duration difference matters for procedures longer than 90 minutes, multi-area treatments (face + neck + decolletage), and large body-surface laser sessions.

When should I use EMLA instead?+

EMLA is appropriate when (a) compound BLT is not accessible, (b) the procedure is superficial and brief (IV access, simple venipuncture), (c) the patient has documented Benzocaine or Tetracaine allergy, (d) the patient is an infant or young child where EMLA has more established pediatric data, or (e) the practitioner cannot enforce BLT's stricter removal protocol.

Is EMLA over the counter?+

EMLA-equivalent low-concentration Lidocaine-Prilocaine formulations are available OTC in many jurisdictions. Higher-strength EMLA and bulk packaging are typically prescription. In the US, branded EMLA is FDA-approved as Rx; generic OTC equivalents exist. Compound BLT is never OTC — it is restricted to licensed providers after NPI verification.

Can I use BLT and EMLA together?+

No. Layering topical anesthetics is not standard practice and is generally avoided. Mixing changes pharmacokinetics unpredictably, increases the risk of exceeding maximum safe doses, and creates ambiguity about removal protocols. If BLT does not provide adequate anesthesia, the next step is regional or local injectable anesthesia, not topical layering. Step up tiers within the MediCaine line (Pro → Ultra) for more depth or duration.

What about BLT vs LMX 4 or LMX 5?+

LMX is OTC single-agent Lidocaine at 4-5%, simpler than EMLA but similar limitations: surface-level numbing, 30-45 min onset, 1-2 hr duration. Compound BLT outperforms LMX on all clinical metrics. LMX is appropriate for OTC settings where compound BLT is not accessible. For licensed providers, compound BLT is the clinical standard.

UPGRADE FROM EMLA TO BLT

If you have NPI verification and you're doing aesthetic, dermatologic, microneedling, or laser work — compound BLT will outperform EMLA every time.

Build Your Order Call (310) 889-0733